Kiora PharmaceuticalsKPRX
About: Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Employees: 12
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
12% more funds holding
Funds holding: 17 [Q2] → 19 (+2) [Q3]
1.6% more ownership
Funds ownership: 47.87% [Q2] → 49.47% (+1.6%) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
10% less capital invested
Capital invested by funds: $5.97M [Q2] → $5.38M (-$594K) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Yi Chen 39% 1-year accuracy 60 / 154 met price target | 206%upside $10 | Buy Reiterated | 12 Nov 2024 |